Overview

Study of Karenitecin (BNP1350) in Patients With Brain Tumors

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate safety and efficacy ofKarenitecin (BNP1350) as a treatment of adults with brain tumors.
Phase:
Phase 2
Details
Lead Sponsor:
BioNumerik Pharmaceuticals, Inc.
Collaborator:
Crown Bioscience
Treatments:
Camptothecin